Follow Whatsapp Channel
Sanofi will first invest 100 million euros ($109.31 million) by next year.
The firm is among three Indian companies whose cough syrups the World Health Organization (WHO) and other agencies have linked to the deaths of 141 children in Uzbekistan, Gambia and Cameroon, in one of the world's worst such waves of poisoning.
At least 70 children in Gambia, most under 5 years old, died from acute kidney injury last year. A government task force which investigated the deaths found they were "a direct result" of contaminated cough and cold syrups imported from India.
Common pharmaceuticals are manufactured using chemical precursors derived from crude oil, presenting a niche sustainability challenge as the world targets Net Zero.
The WHO issued safety alerts last year for Indian-made products found in Gambia and Uzbekistan, and this year in Micronesia and the Marshall Islands.
World Health Organization had found toxins in cough syrups made by three Indian companies.
This is the highest one-time increase in the prices of medicines under the price control regime since the NPPA came into being in 1997.
Health Minister Mansukh Mandaviya said investigations were continuing, and production was suspended at the Marion Biotech unit in Noida, outside Delhi, while a senior executive for the firm said they were awaiting reports following the inspection.
Indian health authorities halted production at Maiden's main factory in Sonepat near New Delhi in October after a WHO report said the company's cough and cold syrups might be connected to the deaths of 69 children in Gambia this year.
In the letter, Somani said the samples of four made-in-India cough syrups linked to the deaths of 66 children in Gambia which were tested in government laboratory here were found to be complying with specifications and not to have been contaminated with DEG or EG according to the test reports.
Results 1-10 of 15
